ISSN: 2376-127X

Journal de la grossesse et de la santé infantile

Accès libre

Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.

Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs

Abstrait

Pregnancy in High-Risk Pulmonary Embolism

Anil Patel

One of the most common causes of maternal mortality in the Western world is pregnancy-associated high-risk pulmonary embolism, which results in hemodynamic instability and circulatory failure due to a significant thrombotic pulmonary blockage. The extremely difficult management of these dramatic conditions includes the necessity to immediately decide between pulmonary reperfusion therapy and hemodynamic replacement while taking both maternal and foetal risks into consideration. The relevance of risk stratification in pregnancy-related PE and the data supporting the use of thrombolysis, catheter-directed thrombectomy thrombolysis, surgical embolectomy, and extracorporeal membrane oxygenation are included in this study. The majority of documented cases of high-risk pregnancy-associated PE have been treated with thrombolysis, with good mother and foetal survival rates, and thrombolysis is recommended by despite the absence of comparison studies and strong evidence. Standards for life-threatening PE. Due to the relatively high risk of bleeding, non-fibrinolytic medications may be selected as a first-line treatment for women in the per partum and early post-partum period, if available. A multidisciplinary strategy involving PE response teams and obstetricians is required in all situations involving pregnancy-associated high-risk PE.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié.